FOLH1 and prostate cancer: Based on molecular subclassification of mCRPC tissues using AR and the neuroendocrine marker synaptophysin (SYP) expression assessed by IHC, most patients with high or heterogeneous STEAP1 and PSMA expression had AR-positive prostate cancer (AR+/SYP- or AR+/SYP+) while those with no PSMA expression had AR-null prostate cancer (AR-/SYP+ or AR-/SYP-).